Screening for tuberculosis among adults newly diagnosed with HIV in Sub-Saharan Africa: A cost-effectiveness analysis

Journal of Acquired Immune Deficiency Syndromes

Volumn 70, Issue 1, 2015, Pages 83-90

  Zwerling, Alice A ^a   Sahu, Maitreyi ^a   Ngwira, Lucky G ^b   Khundi, McEwen ^b   Harawa, Tina ^b   Corbett, Elizabeth L ^b,c   Chaisson, Richard E ^d   Dowdy, David W ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b MALAWI LIVERPOOL WELLCOME TRUST CLINICAL RESEARCH PROGRAMME   (Malawi)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

cost effectiveness; costs and benefits; decision analysis; diagnostic tests; screening; tuberculosis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BACTERIAL DNA; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ANTIBIOTIC THERAPY; CD4 LYMPHOCYTE COUNT; CONFERENCE PAPER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA DETERMINATION; DRUG TREATMENT FAILURE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FLUORESCENCE MICROSCOPE; FLUORESCENCE MICROSCOPY; FOLLOW UP; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; LIGHT EMITTING DIODE; LIGHT EMITTING DIODE FLUORESCENCE MICROSCOPY; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALAWI; MALE; MOLECULAR DIAGNOSTICS; POINT OF CARE TESTING; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCREENING; SENSITIVITY ANALYSIS; TUBERCULOSIS; AFRICA SOUTH OF THE SAHARA; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; MASS SCREENING; PROCEDURES;

ADULT; AFRICA SOUTH OF THE SAHARA; COST-BENEFIT ANALYSIS; HIV INFECTIONS; HUMANS; MASS SCREENING; TUBERCULOSIS;

EID: 84939804901     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000712     Document Type: Conference Paper

References (30)

1. UNAIDS. 2013 UNAIDS Report on the Global AIDS Epidemic. Geneva, Switzerland: UNAIDS; 2013
2. Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008; 22: 1897-1908
3. Lawn SD, Kranzer K, Edwards DJ, et al. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS. 2010; 24: 1323-1328
4. De Cock KM, Chaisson RE. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis. 1999; 3: 457-465
5. Havlir DV, Getahun H, Sanne I, et al. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA. 2008; 300: 423-430
6. Getahun H, Harrington M, OBrien R, et al. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet. 2007; 369: 2042-2049
7. Long R, Scalcini M, Manfreda J, et al. The impact of HIV on the usefulness of sputum smears for the diagnosis of tuberculosis. Am J Public Health. 1991; 81: 1326-1328
8. World Health Organization. Malawi: Tuberculosis Profile 2011. Geneva, Switzerland: WHO; 2011
9. MacPherson P, Corbett EL, Makombe SD, et al. Determinants and consequences of failure of linkage to antiretroviral therapy at primary care level in Blantyre, Malawi: a prospective cohort study. PLoS One. 2012; 7: e44794
10. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA. 2000; 283: 2537-2545
11. Yew WW, Leung CC. Management of multidrug-resistant tuberculosis: update 2007. Respirology. 2008; 13: 21-46
12. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997; 126: 946-954
13. Menzies NA, Cohen T, Lin HH, et al. Population health impact and costeffectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med. 2012; 9: e1001347
14. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a costeffectiveness analysis. PLoS Med. 2011; 8: e1001120
15. Malawi MoH. Clinical Management of HIV in Children and Adults; Lilongwe, Malawi; Malawi Ministry of Health, 2011
16. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2129-2143
17. WHO. Treatment of Tuberculosis; Geneva, Switzerland; World Health Organization, 2006
18. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011; 155: 209-216
19. WHO. Global Tuberculosis Report 2012. Geneva, Switzerland; World Health Organization, 2012
20. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003; 163: 1009-1021
21. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011; 377: 1495-1505
22. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010; 363: 1005-1015
23. Theron G, Peter J, van Zyl-Smit R, et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med. 2011; 184: 132-140
24. WHO. Flourescent Light Emitting Diode (LED) Microscopy for Diagnosis of Tuberculosis: Policy Statement. Geneva, Switzerland; World Health Organization, 2010
25. Shenai S, Minion J, Vadwai V, et al. Evaluation of light emitting diodebased fluorescence microscopy for the detection of mycobacteria in a tuberculosis-endemic region. Int J Tuberc Lung Dis. 2011; 15: 483-488
26. WHO. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva, Switzerland: World Health Organization; 2003
27. World Bank Open Data. Washington, D.C.; The World Bank; 2012
28. Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015; 93: 118-124
29. Andrews JR, Lawn SD, Rusu C, et al. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS. 2012; 26: 987-995
30. Andrews JR, Lawn SD, Dowdy DW, et al. Challenges in evaluating the cost-effectiveness of new diagnostic tests for HIV-Associated tuberculosis. Clin Infect Dis. 2013; 57: 1021-1026